Oasmia Pharmaceutical AB (publ)
Interim report for the period May - July 2010
PHASE III STUDY WITH PACCAL® VET COMPLETED
THE QUARTER IN BRIEF May 1 2010 - July 31 2010
• Consolidated net sales amounted to TSEK 42 (24 657)
• Operating income amounted to TSEK -11 216 (10 624)
• Net income after tax amounted to TSEK -12 090 (9 386)
• Earnings per share was SEK -0,32 (0,28)
• Comprehensive income amounted to TSEK -12 090 (9 386)
• The Phase III study with Paccal® Vet completed
• Oasmia signs a MSEK 75 SEDA agreement
• The Oasmia share is listed on NASDAQ OMX
EVENTS AFTER CLOSING DAY
• Oasmia appoints Carnegie Investment Bank AB as financial advisor
• New MSEK 40 credit facility
• An application for registration of Paccal® Vet has been submitted to EMA
• Clinical study shows good tolerance for Doxophos® Vet
• Oasmia revises financial goal after billion dollar deal in the business
• Two thirds of the patients are enrolled in the Phase III study with Paclical®
• The Phase III study with Paccal Vet submitted to FDA.
